A platform for research: civil engineering, architecture and urbanism
A platform for research: civil engineering, architecture and urbanism
Response to “Comment on sarcopenia and myosteatosis are associated with low survival in patients receiving lenvatinib for unresectable hepatocellular carcinoma”
https://orcid.org/0000-0002-7498-4183
Response to “Comment on sarcopenia and myosteatosis are associated with low survival in patients receiving lenvatinib for unresectable hepatocellular carcinoma”
https://orcid.org/0000-0002-7498-4183
Response to “Comment on sarcopenia and myosteatosis are associated with low survival in patients receiving lenvatinib for unresectable hepatocellular carcinoma”
https://orcid.org/0000-0002-7498-4183
Response to “Comment on sarcopenia and myosteatosis are associated with low survival in patients receiving lenvatinib for unresectable hepatocellular carcinoma”
Journal of the Formosan Medical Association
Luo, Pei-Jui (author) / Wu, Chih-Horng (author)
2025-02-01
Article (Journal)
Electronic Resource
English
Lactylation‐Driven HECTD2 Limits the Response of Hepatocellular Carcinoma to Lenvatinib
| Wiley | 2025
| Elsevier | 2024
Hepatocellular carcinoma disguised as liver abscesses
| British Library Online Contents | 2018